STOCK TITAN

The Oncology Institute (TOI) Stock Price, News & Analysis

TOI NASDAQ

Ticker history: TOI became STLN (Starling Oncology, Inc.) on .

Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
65 252 sessions, August 1, 2025 to August 3, 2026
Largest daily move
+28.9% close of November 14, 2025
1-year change
+37.5% closing prices, August 1, 2025 to August 3, 2026
1-month change
-2.8% closing prices, July 2, 2026 to August 3, 2026

Company Description

The Oncology Institute, Inc. (NASDAQ: TOI) is a healthcare company focused on oncology care in the community setting. According to the company, it is one of the largest value-based oncology groups in the United States and operates within the health care and social assistance sector. TOI states that it is advancing oncology by delivering highly specialized, value-based cancer care outside of traditional hospital environments, with an emphasis on evidence-based medicine and cost-effective care for cancer patients.

Founded in 2007, The Oncology Institute describes itself as a pioneer in value-based community oncology care. The company reports that it offers cancer care to a population of approximately 1.9 million patients through over 180 employed and affiliate clinicians and more than 100 clinics and affiliate locations of care across five states. TOI highlights that it is changing oncology for the better by pairing specialized clinical expertise with care models that are designed to manage total cost of care while maintaining quality.

Business model and care approach

The Oncology Institute presents its business as centered on value-based cancer care delivered in the community setting. In its public statements, TOI characterizes itself as a value-based oncology group and a value-based oncology practice. This reflects a focus on arrangements where reimbursement is tied to quality and cost outcomes rather than only to the volume of services. The company also references delegated capitated models and capitation revenue in its outlook, indicating that some of its contracts involve fixed payments per patient for comprehensive oncology services.

TOI notes that it participates in models sponsored by the Centers for Medicare & Medicaid Services (CMS), including the Enhancing Oncology Model. Through its California professional corporation, the company reports having generated Medicare savings in this program while earning high quality scores on measures such as avoidable emergency department visits and admissions. TOI links these results to programs such as its High Value Cancer Care program, health care coaching, and 24/7 symptom management support designed to keep patients on treatment and reduce unnecessary hospital utilization.

Clinical services and care delivery

According to TOI’s own descriptions, the organization offers evidence-based cancer care that includes access to clinical trials and transfusions. The company states that it delivers care models traditionally associated with advanced care delivery organizations, but in community locations. In earlier descriptions, TOI has also referenced services such as infusion centers, an in-house dispensary, outpatient blood transfusion, outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. These services are grouped into operating segments that include a dispensary segment, patient services, and clinical trials and others, with patient services identified as the primary source of revenue.

TOI emphasizes that its model is designed to bring specialized oncology care closer to where patients live. It describes its clinics and affiliate locations as community-based, and it highlights the combination of clinical trials and other advanced care delivery models with local access. The company also notes that patients across its markets have access to best practices developed in its value-based programs, such as proactive navigation and real-time symptom management.

Scale, footprint, and organization

The Oncology Institute reports that it serves a large and growing patient base through a network of clinics and affiliated sites. Public communications from the company state that TOI has over 180 employed and affiliate clinicians and more than 100 clinics and affiliate locations of care across five states. TOI also notes that it is expanding delegated contracts in markets such as Florida and that it operates a pharmacy and dispensary business that contributes meaningfully to revenue and gross profit.

The company is headquartered in Cerritos, California, as reflected in its SEC filings, and its common stock and redeemable warrants trade on The Nasdaq Stock Market LLC under the symbols TOI and TOIIW, respectively. TOI identifies itself as an emerging growth company in certain SEC filings, which can affect its reporting and disclosure framework under U.S. securities laws.

Technology, operations, and partnerships

In its public updates, TOI has highlighted the use of technology and automation to support its operations. The company has described efforts to leverage artificial intelligence to drive efficiencies in operations and improve the patient experience. For example, TOI announced a co-development partnership with Ascertain, a healthcare technology company, to create near-touchless administrative workflows for payer-related tasks ahead of outpatient oncology visits. The collaboration uses an AI-powered automation module to streamline prior authorization processes and other payer interactions, with TOI reporting substantial reductions in authorization workload and submission time at pilot sites.

TOI has also referenced a technology-enabled care delivery platform and enterprise-level data privacy and security practices in connection with its leadership appointments. These statements indicate that the company views technology and data as important components of its value-based care model and operational strategy.

Participation in value-based programs and Medicare models

The Oncology Institute has publicly discussed its participation in CMS programs aimed at advancing high-quality, person-centered, and equitable cancer care. In particular, the company has reported results from the Enhancing Oncology Model, a voluntary total-cost-of-care model for Medicare Fee-for-Service beneficiaries. TOI states that it achieved Medicare savings and earned maximum quality points on certain measures, attributing these outcomes to proactive navigation, high-value care programs, and around-the-clock symptom management support.

The company also notes a prior track record in CMS’s Oncology Care Model, where it reports having exceeded quality standards and generated savings for Medicare. These disclosures underscore TOI’s emphasis on value-based arrangements and its focus on both clinical outcomes and cost management within oncology.

Financial orientation and segments

In its communications to investors, The Oncology Institute has described its revenue mix and operating segments. The company identifies three operating segments: dispensary, patient services, and clinical trials and others. It has stated that key revenue is earned from providing patient services and that the majority of revenue comes from patient services. TOI has also discussed fee-for-service revenue growth, retail pharmacy and dispensary performance, and capitation revenue as components of its financial profile.

TOI uses non-GAAP metrics such as Adjusted EBITDA and Free Cash Flow as additional tools to assess operational and financial performance, as described in its press releases and SEC filings. The company provides reconciliations of these measures to the most comparable GAAP metrics and explains the types of adjustments included, such as depreciation, amortization, interest, taxes, non-cash items, share-based compensation, changes in fair value of liabilities, and certain consulting and infrastructure costs.

Stock listing and regulatory disclosures

The Oncology Institute, Inc. files periodic and current reports with the U.S. Securities and Exchange Commission. Its common stock, with a par value of $0.0001 per share, is listed on Nasdaq under the symbol TOI, and its redeemable warrants are listed under the symbol TOIIW. SEC filings indicate that the company has reported various material events, including financial results, guidance updates, cybersecurity incidents affecting a software provider, changes to the Board of Directors, and the use of investor presentations.

Through these filings, TOI provides information on its financial condition, results of operations, governance changes, and certain operational developments. Investors can review these documents for detailed historical financial data, risk factors, and descriptions of non-GAAP measures used by the company.

Stock Performance

$5.13
No recent trading
Last close: August 3, 2026
+37.5%
1 year to August 3, 2026

The Oncology Institute (TOI) closed at $5.13 on August 3, 2026. In the 12 months to August 3, 2026, the price gained 37.5%.

See what a $1,000 investment in TOI was worth at its last close

TOI Metrics & Rankings

Price returns through August 3, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

The Oncology Institute has 10 recent news articles. Of the recent coverage, 8 articles coincided with positive price movement and 1 with negative movement. Key topics include conferences, earnings date, earnings. View all TOI news →

Financial Highlights

The Oncology Institute generated $502.7M in revenue in FY2025, and operating income reached -$36.1M (-7.2% operating margin). Diluted earnings per share stood at -$0.54. The company generated -$24.6M in operating cash flow. The current ratio was 1.59, measuring current assets divided by current liabilities.

$502.7M
Revenue (FY2025)
-$24.6M
Operating Cash Flow

Upcoming Events

YEAR
2031
2031 Financial

Term Loan Maturity

New $75M OrbiMed term loan maturing in 2031, replacing an $86M convertible note; no specific maturity date provided.

The Oncology Institute has 1 upcoming scheduled event. The next event, "Term Loan Maturity", is expected in 2031. It is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the TOI stock price.

Short Interest History

Last 12 Months

Short interest in The Oncology Institute (TOI) currently stands at 7.2 million shares, down 1.6% from the previous reporting period.

Days to Cover History

Last 12 Months

Days to cover for The Oncology Institute (TOI) currently stands at 4.8 days, up 55.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 141.5%. Across the settlements charted above, it has ranged from 2.0 to 7.6 days.

TOI Company Profile & Sector Positioning

The Oncology Institute (TOI) operates in the Medical Care Facilities industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing TOI often look at related companies in the same sector, including Astrana Health Inc. (ASTH), Concentra Group Holdings Parent, Inc. (CON), Pediatrix Medical Group, Inc. (MD), InnovAge Holding Corp. (INNV), and Universal Health Services, Inc. (UHS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TOI's relative position within its industry.

Frequently Asked Questions

The Oncology Institute (TOI) has no recent trading. Its last close was $5.13 on August 3, 2026. The company now trades as STLN.

The FY2025 revenue of The Oncology Institute (TOI) is $502.7M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of The Oncology Institute (TOI) is -$0.54 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of The Oncology Institute (TOI) is -$24.6M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The operating profit margin of The Oncology Institute (TOI) is -7.2% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The current ratio of The Oncology Institute (TOI), current assets divided by current liabilities, was 1.59 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of The Oncology Institute (TOI) is -$36.1M for FY2025, its most recent completed fiscal year. Learn about operating income.

The Oncology Institute, Inc. is a healthcare company focused on oncology care in the community setting. It describes itself as one of the largest value-based oncology groups in the United States, delivering specialized, evidence-based cancer care through clinics and affiliate locations across multiple states.

TOI operates in the health care and social assistance sector and is associated with the offices of physicians (except mental health specialists) industry. Its activities center on oncology services delivered in community-based settings.

The Oncology Institute defines its business model as value-based cancer care. It references delegated capitated arrangements, capitation revenue, and participation in CMS total-cost-of-care models, focusing on both clinical outcomes and cost management in oncology.

According to the company, TOI provides oncology services that include infusion centers, an in-house dispensary, outpatient blood transfusion, outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling, organized into segments such as dispensary, patient services, and clinical trials and others.

TOI reports that it has over 100 clinics and affiliate locations of care across five states, serving a population of approximately 1.9 million patients. It emphasizes delivering oncology care in community settings rather than only in large hospital centers.

The company has disclosed participation in CMS programs such as the Enhancing Oncology Model and previously the Oncology Care Model. It reports achieving Medicare savings and high quality scores, linking these outcomes to programs like its High Value Cancer Care program and 24/7 symptom management support.

TOI identifies three operating segments: dispensary, patient services, and clinical trials and others. It states that key revenue is earned from providing patient services and that the majority of its revenue comes from patient services, with additional contributions from the dispensary and other segments.

TOI highlights a technology-enabled care delivery platform and efforts to leverage AI to improve operational efficiency and the patient experience. It has announced a partnership with Ascertain to co-develop AI-based automation for administrative workflows, particularly around payer-related tasks and prior authorizations.

According to its SEC filings, The Oncology Institute, Inc.’s common stock is listed on The Nasdaq Stock Market LLC under the ticker symbol TOI. Its redeemable warrants are listed on Nasdaq under the symbol TOIIW.

The Oncology Institute states that it was founded in 2007. Since its founding, the company has focused on advancing oncology by delivering highly specialized, value-based cancer care in the community setting, including access to clinical trials and transfusions.